title: [U-HO1. A new cell line derived from a primary refractory classical Hodgkin lymphoma].
abstract: The Hodgkin cell line U-HO1 was established from a malignant pleural effusion of a 23-yr-old male patient during the end stage of refractory nodular sclerosing classical Hodgkin lymphoma (cHL). Since its establishment in 2005, U-HO1 has maintained stable characteristics in vitro and has a doubling time of about 4 days under standard culture conditions. U-HO1 forms typical Reed/Sternberg cells in suspension, is EBV negative, lacks HLA-ABC- but expresses HLA-D- proteins/CD74 and surface exposes CD15 together with CD30 in the absence of CD19 and CD20. Karyotype analysis of U-HO1 revealed a hyperdiploid karyotype with multiple clonal aberrations. Most significant is an elongated chromosome 2, der(2)t(2;10)(q35;q16.1)add(2)(p13). CGH analysis revealed the following imbalances: ish cgh dim(1)(p13p31)(p12q21), enh(2)(p13p23), dim(4)(q31.3qter), enh(6)(q22q27), enh(12), enh(18),enh(20)(q13.1pter). FISH analysis showed about six-fold amplification of REL and BCL-11A, thus, U-HO1 is prototypical for cHL in every aspect tested so far. Compared to other HL cell lines, U-HO1 proved far less genetically aberrant suggesting that U-HO1's imbalances suffice to cause the full-blown phenotype of primary refractory cHL.
authors.affiliation: Institut für Pathologie, Klinikum Ulm, Albert-Einstein-Allee 11, 89081 Ulm. peter.moeller@uniklinik-ulm.de
authors.forename: P
authors.initials: P
authors.lastname: Möller
authors.forename: A
authors.initials: A
authors.lastname: Mader
authors.forename: T F E
authors.initials: TF
authors.lastname: Barth
authors.forename: S
authors.initials: S
authors.lastname: Brüderlein
mesh_terms: D000328:Adult; D022981:Allelic Imbalance / Q000235:genetics; D002455:Cell Division / Q000235:genetics / Q000502:physiology; D045744:Cell Line, Tumor; D002889:Chromosomes, Human, Pair 2 / Q000235:genetics; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006681:HLA-D Antigens / Q000032:analysis; D006689:Hodgkin Disease / Q000188:drug therapy / Q000235:genetics / Q000473:pathology* / Q000532:radiotherapy; D006801:Humans; D008297:Male; D010641:Phenotype; D016066:Pleural Effusion, Malignant / Q000235:genetics / Q000473:pathology*; D016539:Reed-Sternberg Cells / Q000473:pathology
chemical_list: D006681:HLA-D Antigens